Exam Quality of Ultrasound and Dynamic Contrast-enhanced Abbreviated MRI and Impact on Early-stage HCC Detection

Overview

Journal Abdom Radiol (NY)

Publisher Springer

Specialties Gastroenterology
Radiology

Date 2024 Nov 14

PMID 39542949

Authors

Karim Seif El Dahan

Takeshi Yokoo

Mishal Mendiratta-Lala

David Fetzer

Matthew Davenport

Darine Daher

Nicole E Rich

Edward Yang

Neehar D Parikh

Amit G Singal

Affiliations

Soon will be listed here.

Abstract

Purpose: MRI is a potential alternative to ultrasound for hepatocellular carcinoma (HCC) detection. We evaluated the impact of ultrasound and dynamic abbreviated MRI (AMRI) exam quality on early-stage HCC detection.

Methods: We conducted a multicenter case-control study among patients with cirrhosis (cases with early-stage HCC per Milan Criteria; controls without HCC) who underwent both a liver ultrasound and dynamic contrast-enhanced (DCE) AMRI within 6 months in 2012-2019. Two radiologists performed independent, blinded interpretations of both exams for HCC detection and scored exam quality as no/mild, moderate, or severe limitations. Associations between exam quality, patient characteristics, and HCC detection were assessed by odds ratios (OR).

Results: Of 216 cases and 432 controls, severe limitations were reported in 7% and 8% of ultrasounds and DCE-AMRIs, respectively. Severe limitations at ultrasound were associated with obesity (OR 2.08, 95%CI [1.32-3.32]) and metabolic dysfunction-associated steatotic liver disease (MASLD) (OR 1.98 [1.12-3.44]) but not for DCE-AMRI. Decompensated cirrhosis (Child-Pugh C) was associated with severe limitations for both ultrasound (OR 2.54 [1.37-4.58]) and DCE-AMRI (OR 3.96 [2.36-6.58]). Compared to exams with no/mild limitations, exams with severe limitations had lower sensitivity for ultrasound (79.6% vs. 21.7%, P < 0.001) and AMRI (86.1% vs. 50.0%, P = 0.001). In patients in whom ultrasound was severely limited, DCE-AMRI had significantly higher odds of early-stage HCC detection than ultrasound (OR 8.23 [1.25-54.02]).

Conclusions: HCC detection by DCE-AMRI may be preferred in patients with severe limitations at ultrasound due to obesity and MASLD. Both modalities remain limited for patients with decompensated cirrhosis, for whom alternative strategies may be needed.

References

Huang D, Singal A, Kono Y, Tan D, El-Serag H, Loomba R . Changing global epidemiology of liver cancer from 2010 to 2019: NASH is the fastest growing cause of liver cancer. Cell Metab. 2022; 34(7):969-977.e2. PMC: 9762323. DOI: 10.1016/j.cmet.2022.05.003. View

Arnold M, Abnet C, Neale R, Vignat J, Giovannucci E, McGlynn K . Global Burden of 5 Major Types of Gastrointestinal Cancer. Gastroenterology. 2020; 159(1):335-349.e15. PMC: 8630546. DOI: 10.1053/j.gastro.2020.02.068. View

Khalaf N, Ying J, Mittal S, Temple S, Kanwal F, Davila J . Natural History of Untreated Hepatocellular Carcinoma in a US Cohort and the Role of Cancer Surveillance. Clin Gastroenterol Hepatol. 2016; 15(2):273-281.e1. DOI: 10.1016/j.cgh.2016.07.033. View

Reig M, Forner A, Rimola J, Ferrer-Fabrega J, Burrel M, Garcia-Criado A . BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update. J Hepatol. 2021; 76(3):681-693. PMC: 8866082. DOI: 10.1016/j.jhep.2021.11.018. View

Loomba R, Lim J, Patton H, El-Serag H . AGA Clinical Practice Update on Screening and Surveillance for Hepatocellular Carcinoma in Patients With Nonalcoholic Fatty Liver Disease: Expert Review. Gastroenterology. 2020; 158(6):1822-1830. PMC: 8012107. DOI: 10.1053/j.gastro.2019.12.053. View

Tzartzeva K, Obi J, Rich N, Parikh N, Marrero J, Yopp A . Surveillance Imaging and Alpha Fetoprotein for Early Detection of Hepatocellular Carcinoma in Patients With Cirrhosis: A Meta-analysis. Gastroenterology. 2018; 154(6):1706-1718.e1. PMC: 5927818. DOI: 10.1053/j.gastro.2018.01.064. View

Singal A, Conjeevaram H, Volk M, Fu S, Fontana R, Askari F . Effectiveness of hepatocellular carcinoma surveillance in patients with cirrhosis. Cancer Epidemiol Biomarkers Prev. 2012; 21(5):793-9. PMC: 5640437. DOI: 10.1158/1055-9965.EPI-11-1005. View

Singal A, Nehra M, Adams-Huet B, Yopp A, Tiro J, Marrero J . Detection of hepatocellular carcinoma at advanced stages among patients in the HALT-C trial: where did surveillance fail?. Am J Gastroenterol. 2013; 108(3):425-32. PMC: 5560895. DOI: 10.1038/ajg.2012.449. View

Chong N, Schoenberger H, Yekkaluri S, Fetzer D, Rich N, Yokoo T . Association between ultrasound quality and test performance for HCC surveillance in patients with cirrhosis: a retrospective cohort study. Aliment Pharmacol Ther. 2022; 55(6):683-690. DOI: 10.1111/apt.16779. View

10.

Schoenberger H, Chong N, Fetzer D, Rich N, Yokoo T, Khatri G . Dynamic Changes in Ultrasound Quality for Hepatocellular Carcinoma Screening in Patients With Cirrhosis. Clin Gastroenterol Hepatol. 2021; 20(7):1561-1569.e4. PMC: 8660956. DOI: 10.1016/j.cgh.2021.06.012. View

11.

Kim Y, An C, Kim D, Aljoqiman K, Choi J, Kim M . Failure of hepatocellular carcinoma surveillance: inadequate echogenic window and macronodular parenchyma as potential culprits. Ultrasonography. 2019; 38(4):311-320. PMC: 6769189. DOI: 10.14366/usg.18051. View

12.

Simmons O, Fetzer D, Yokoo T, Marrero J, Yopp A, Kono Y . Predictors of adequate ultrasound quality for hepatocellular carcinoma surveillance in patients with cirrhosis. Aliment Pharmacol Ther. 2016; 45(1):169-177. PMC: 7207219. DOI: 10.1111/apt.13841. View

13.

Henrique Lima P, Fan B, Berube J, Cerny M, Olivie D, Giard J . Cost-Utility Analysis of Imaging for Surveillance and Diagnosis of Hepatocellular Carcinoma. AJR Am J Roentgenol. 2019; 213(1):17-25. DOI: 10.2214/AJR.18.20341. View

14.

Gupta P, Soundararajan R, Patel A, Kumar-M P, Sharma V, Kalra N . Abbreviated MRI for hepatocellular carcinoma screening: A systematic review and meta-analysis. J Hepatol. 2021; 75(1):108-119. DOI: 10.1016/j.jhep.2021.01.041. View

15.

Park H, Kim S, Singal A, Lee S, Won H, Byun J . Abbreviated magnetic resonance imaging vs ultrasound for surveillance of hepatocellular carcinoma in high-risk patients. Liver Int. 2021; 42(9):2080-2092. DOI: 10.1111/liv.15110. View

16.

Yoon J, Lee J, Lee D, Joo I, Jeon J, Ahn S . A Comparison of Biannual Two-Phase Low-Dose Liver CT and US for HCC Surveillance in a Group at High Risk of HCC Development. Liver Cancer. 2020; 9(5):503-517. PMC: 7548851. DOI: 10.1159/000506834. View

17.

Kim S, An J, Lim Y, Han S, Lee J, Byun J . MRI With Liver-Specific Contrast for Surveillance of Patients With Cirrhosis at High Risk of Hepatocellular Carcinoma. JAMA Oncol. 2016; 3(4):456-463. PMC: 5470420. DOI: 10.1001/jamaoncol.2016.3147. View

18.

Terzi E, Iavarone M, Pompili M, Veronese L, Cabibbo G, Fraquelli M . Contrast ultrasound LI-RADS LR-5 identifies hepatocellular carcinoma in cirrhosis in a multicenter restropective study of 1,006 nodules. J Hepatol. 2017; 68(3):485-492. DOI: 10.1016/j.jhep.2017.11.007. View

19.

Quek J, Tan D, Chan K, Lim W, Ng C, Ren Y . Quality Assessment of Ultrasound and Magnetic Resonance Imaging for Hepatocellular Carcinoma Surveillance: A Systematic Review and Meta-Analysis. Dig Dis. 2023; 41(5):757-766. DOI: 10.1159/000531016. View

20.

Yokoo T, Masaki N, Parikh N, Lane B, Feng Z, Mendiratta-Lala M . Multicenter Validation of Abbreviated MRI for Detecting Early-Stage Hepatocellular Carcinoma. Radiology. 2023; 307(2):e220917. PMC: 10102624. DOI: 10.1148/radiol.220917. View